Investors
Frazier Healthcare Ventures
http://www.frazierhealthcare.com
Founded in 1991 and with more than $1.2 billion of capital under management, Frazier Healthcare is one of the nation's leading providers of venture and growth equity capital to emerging healthcare companies. Having invested in more than 85 emerging healthcare companies, Frazier Healthcare is well known for its depth of experience and the technical expertise of its investment team. This experience encompasses product development and launch, clinical trial implementation and design, industry operating experience, academic research and clinical practice.
Pappas Ventures
Pappas Ventures is a life sciences venture capital firm located in the Research Triangle area of North Carolina. Since 1994 we have been investing in and nurturing promising young companies, while delivering superior results to investors and entrepreneurs alike. We have $230 million in capital under management and have invested in more than 30 portfolio companies throughout the United States.
Panorama Capital (J.P. Morgan Partners, LLC)
http://www.panoramacapital.com
J.P. Morgan Partners, LLC (JPMP) is a leading private equity firm with approximately $10 billion in capital under management as of March 31, 2006. Since its inception in 1984, JPMP has invested over $15 billion worldwide in consumer, media, energy, industrial, financial services, healthcare, and technology companies. Selected medical device investments include: CardioKinetix, dj Orthopedics, FlowCardia, Innotech, Innovative Spinal Technologies, Kinetic Concepts, Novasys Medical, PowerVision, and ProRythym.
The JPMP team became independent from JPMorgan Chase in late 2006 and established two separate, highly focused platforms. The venture team formed Panorama Capital, LLC, which focuses on leading investments in emerging technology and life sciences companies. The buyout/growth equity professionals formed CCMP Capital, LLC, which focuses exclusively on lead buyout and growth equity investments primarily in its six targeted industry sectors in the U.S. and Europe. JPMP Asia, known as CCMP Capital Asia, continues to invest in the Asia/Pacific region and will maintain its affiliation with the buyout professionals of CCMP Capital.
JPMP is a private equity division of JPMorgan Chase & Co. (NYSE: JPM), one of the largest financial institutions in the United States, and is a registered investment adviser with the Securities and Exchange Commission.
Gilde Healthcare Partners
Gilde Healthcare Partners is a European venture capital firm with more than $380 million under management. It primarily invests in emerging companies working within the therapeutic, diagnostic and medical device sectors. Gilde's experience in venture capital dates back to the company's inception in 1982. Gilde has a successful track record of funding entrepreneurs and establishing successful, enduring companies. Since 2000, Gilde Healthcare Partners has invested in many companies across Europe and the US and realized several successful exits. In most of its investments Gilde acts as a lead investor and becomes involved at board level.
Life Sciences Partners
LSP (Life Sciences Partners) is a leading independent European venture capital firm, providing private equity financing to early- to mid-stage life-science companies. Since the late 1980s, LSP's management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. For example, LSP was a founding investor in Crucell, DNage, Qiagen, Rhein Biotech and Pharming. With EUR 400 million under management and offices in Amsterdam, Munich and Boston, LSP is one of Europe's largest and most experienced specialist life-science investors.
New Science Ventures
http://www.newscienceventures.com
(NSV) is a New York-based venture capital firm which invests in both early and late stage companies using novel scientific approaches to address significant unmet needs and create order of magnitude improvements in performance. NSV manages over $125 million and has invested in more than 20 companies located in the US, Europe, India and China in the life sciences and information technology sectors.
H&Q Healthcare Investors
H&Q Healthcare Investors ("HQH") is a broadly diversified closed-end healthcare fund traded on the New York Stock Exchange under the ticker HQH. HQH primarily invests in biotechnology, medical devices, and pharmaceuticals. The Fund's objective is to provide long-term capital appreciation through investments in companies in the health technology industries believed to have significant potential for above-average long-term growth. Selection will emphasize the smaller, emerging companies with a maximum of 40% of the Fund's assets in restricted securities of both public and private companies. Management believes this provides a unique opportunity not usually available to mutual fund investors.